CDK6 and neoplasm: While CDK6 amplification and overexpression is observed in about 25% of MFS and correlates with poor patient prognosis [60], more extensive genomic analyses of patient samples at different stages of tumor development paired with functional studies in pre-clinical models are needed to determine if CDK6 is a true driver of MFS.